Fresenius Kabi Introduces Linezolid Injection 600 mg per 300 mL in Freeflex® Bags

LAKE ZURICH, Ill., April 21, 2016 – Fresenius Kabi announced today it has introduced the anti-infective Linezolid Injection in 600 mg per 300 mL Freeflex® bags. This generic alternative to Zyvox® is a new offering from Fresenius Kabi and is available immediately for U.S. customers.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

“As antibiotic resistance continues to challenge healthcare providers and patients, Fresenius Kabi is pleased to offer a new generic option for the treatment of patients with very serious infections,” said John Ducker, president and CEO of Fresenius Kabi USA. “Fresenius Kabi Linezolid injection will also feature a new foil overwrap with differentiated color labeling on both sides to help clinicians identify the product and strength.”

Linezolid is the fourth premix bag Fresenius Kabi has introduced in the United States since 2013 using the company’s proprietary Freeflex delivery system.

Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions. Benefits arise from its patented port technology, clear labeling and innovative product concept, helping to provide pharmacies and clinicians greater confidence in delivering critical therapies.

The Freeflex delivery system has been marketed globally since 2005 and in the U.S. since 2008.

Indications
Linezolid injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial and Community-acquired pneumonia, Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, Uncomplicated skin and skin structure infections, and Vancomycin-resistant Enterococcus faecium infections.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.

Zyvox® is a registered trademark of Pfizer Inc.

Media Contact
Matt Kuhn
847-550-5751
matt.kuhn@fresenius-kabi.com